Clinical trials: Heart Failure with Reduced Ejection Fraction HFrEF
- Condition Heart Failure with Reduced Ejection Fraction HFrEF
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Chronic Heart Failure With Reduced Ejection Fraction
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug.
- Trial name
- NCT02226120
- Testing
- LCZ696
- Where
- 394 sites in United States, Argentina and 39 more
- Volunteers
- 1,980 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with…
- Trial name
- HFrEF (NCT02880618)
- Testing
- Barostim Neo™ System
- Where
- 30 sites in Germany, Italy
- Volunteers
- 500 people
- Sponsor
- CVRx, Inc.